---
title: "Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC"
description: "UBS Asset Management Americas LLC reduced its stake in Twist Bioscience Co. (NASDAQ:TWST) by 3.0% in Q4, now holding 853,675 shares valued at $39.67 million. Other investors like Vanguard and ARK Inve"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241964847.md"
published_at: "2025-05-27T08:40:37.000Z"
---

# Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

> UBS Asset Management Americas LLC reduced its stake in Twist Bioscience Co. (NASDAQ:TWST) by 3.0% in Q4, now holding 853,675 shares valued at $39.67 million. Other investors like Vanguard and ARK Investment Management increased their stakes. Analysts have mixed ratings on TWST, with a consensus rating of "Moderate Buy" and an average price target of $50.40. Twist Bioscience's stock opened at $28.26, with a market cap of $1.69 billion. The company reported a quarterly EPS of ($0.66), missing estimates, and is expected to post -2.12 EPS for the current year.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 3.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 853,675 shares of the company's stock after selling 26,524 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 1.43% of Twist Bioscience worth $39,670,000 at the end of the most recent reporting period.

Get **Twist Bioscience** alerts:

Several other institutional investors have also recently added to or reduced their stakes in TWST. Vanguard Group Inc. increased its stake in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company's stock valued at $269,860,000 after purchasing an additional 189,791 shares during the last quarter. ARK Investment Management LLC increased its stake in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company's stock valued at $260,040,000 after purchasing an additional 237,772 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock valued at $69,972,000 after purchasing an additional 532,040 shares during the last quarter. Geode Capital Management LLC increased its stake in Twist Bioscience by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company's stock valued at $63,895,000 after purchasing an additional 6,908 shares during the last quarter. Finally, First Light Asset Management LLC bought a new stake in Twist Bioscience during the fourth quarter valued at $56,984,000.

## Analysts Set New Price Targets

Several analysts have weighed in on TWST shares. Scotiabank reiterated an "outperform" rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Guggenheim reiterated a "buy" rating and set a $50.00 target price on shares of Twist Bioscience in a research note on Tuesday, May 6th. JPMorgan Chase & Co. lowered their target price on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group lowered their target price on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Twist Bioscience presently has a consensus rating of "Moderate Buy" and an average price target of $50.40.

**Check Out Our Latest Stock Report on TWST**

## Twist Bioscience Stock Up 0.4%

Twist Bioscience stock opened at $28.26 on Monday. The company has a 50-day simple moving average of $36.71 and a 200-day simple moving average of $42.81. The firm has a market capitalization of $1.69 billion, a P/E ratio of -8.36 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. Twist Bioscience Co. has a one year low of $27.12 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. As a group, equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

## Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,802 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total value of $83,359.50. Following the completion of the transaction, the chief executive officer now owns 649,630 shares in the company, valued at $19,326,492.50. This represents a 0.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Patrick John Finn sold 1,877 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $29.75, for a total transaction of $55,840.75. Following the completion of the transaction, the chief operating officer now owns 240,783 shares of the company's stock, valued at $7,163,294.25. This represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,011 shares of company stock worth $951,499 in the last 90 days. Corporate insiders own 3.01% of the company's stock.

## Twist Bioscience Company Profile

(Free Report)

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

## Recommended Stories

-   Five stocks we like better than Twist Bioscience
-   Are Penny Stocks a Good Fit for Your Portfolio?
-   This Market Sell-Off Might Trigger a Value Rotation Into Pepsi
-   What is a Bond Market Holiday? How to Invest and Trade
-   Alphabet Stock Lags—But Waymo May Be Its Hidden Driver
-   How to Buy Gold Stock and Invest in Gold
-   Trade Desk Silences Critics; Recovery Looks Poised to Continue

**Want to see what other hedge funds are holding TWST?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

*This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.*

## Should You Invest $1,000 in Twist Bioscience Right Now?

Before you consider Twist Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.

While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

### Related Stocks

- [TWST.US - Twist Bioscience](https://longbridge.com/en/quote/TWST.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Twist Bioscience stellt neue Library-Preparation-Kits für präzisere Genomsequenzierung vor | Twist Bioscience Corporation has announced the launch of new Twist TrueAmp Library Preparation Kits and Twist PCR-Free W | [Link](https://longbridge.com/en/news/275462378.md) |
| Twist Bioscience Corporation published an update to their financial calendar | Twist Bioscience Corporation will announce its financial results for Q1 of fiscal 2026 on February 2, 2026, before marke | [Link](https://longbridge.com/en/news/272273925.md) |
| Twist Bioscience President and COO Patrick John Finn Reports Disposal of Common Shares | Patrick John Finn, President and COO of Twist Bioscience Corporation, reported the disposal of common shares of the comp | [Link](https://longbridge.com/en/news/272746654.md) |
| Twist Bioscience (NASDAQ:TWST) Insider Sells $11,197.44 in Stock | Twist Bioscience (NASDAQ:TWST) insider Dennis Cho sold 324 shares for $11,197.44 on December 22nd. Following the sale, C | [Link](https://longbridge.com/en/news/270661243.md) |
| Twist Bioscience (NASDAQ:TWST) Insider Sells $51,191.42 in Stock | Twist Bioscience insider Dennis Cho sold 1,099 shares at $46.58, totaling $51,191.42, reducing his stake by 0.76%. Post- | [Link](https://longbridge.com/en/news/275144658.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
